Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial

The observational prospective trial herein presented aimed at evaluating the efficacy of fulvestrant 500 mg in the treatment of endocrine sensitive advanced breast cancer patients from the real world setting. The primary end point was clinical benefit rate (CBR). Secondary end points were overall su...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Moscetti, Luca, Fabbri, Maria Agnese, Natoli, Clara, Vici, Patrizia, Gamucci, Teresa, Sperduti, Isabella, Iezzi, Laura, Iattoni, Elena, Pizzuti, Laura, Roma, Carmine, Vaccaro, Angela, D’Auria, Giuliana, Mauri, Mariella, Mentuccia, Lucia, Grassadonia, Antonino, Barba, Maddalena, Ruggeri, Enzo Maria
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5589600/
https://ncbi.nlm.nih.gov/pubmed/28903361
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17262
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados